- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00112112
Safety Study to Evaluate FluMist in Immunocompromised Children
A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of Age
Study Overview
Detailed Description
This study is a randomized, double-blind Phase 1 study of FluMist vs. placebo in mild to moderately immunocompromised children 5 to 17 years of age with cancer. The primary objective of this study is to describe the safety of FluMist compared with placebo in mild to moderately immunocompromised children with cancer. The secondary objectives of this study are to describe the immune responses following vaccination with FluMist and to determine the incidence and duration of viral replication following vaccination with FluMist.
The standard 0.5 mL dose of vaccine or placebo was administered intranasally. Patients were evaluated at four visits scheduled between days 3-5, days 7-10, days 14-28, and days 35-42 for viral shedding via nasal swabs. Safety outcomes were collected at study clinic visits or by telephone contact through 42 days post dose. Serious adverse events and significant new medical conditions were collected through 180 days after receipt of investigational product.
Immune responses were measured by detection of influenza-specific antibodies as measured by the standard hemagglutination inhibition (HAI) assay. Influenza-specific serum antibody isotype levels were determined and nasal swab specimens were analyzed for the expression of influenza-specific immunoglobulin A (IgA). Serum was analyzed for its ability to neutralize viral particles from infecting Madin-Darby canine kidney cells (microneutralization). Baseline immunosuppression as measured by expression of T- and B-lymphocyte subsets was compared to immunosuppression at time points after vaccination. The duration of viral replication and the titers of live-attenuated influenza virus shed was evaluated from nasal swab specimens collected at scheduled time points after administration of FluMist.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester School of Medicine & Dentistry
-
Stony Brook, New York, United States, 11794
- Stony Brook University Medical Center
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude's Children's Research Hospital
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University
-
-
Washington
-
Seattle, Washington, United States, 98105
- Children's Hospital Regional Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 5 through 17 years of age (not yet reached their 18th birthday) at the time of entry into the study;
- Patient's parent or legal guardian available by telephone during the course of the study;
- Written informed consent (assent if applicable) and Health Insurance Portability and Accountability Act (HIPAA) authorization (if applicable) obtained from the patient's parent or legal guardian;
- Ability of the patient or patient's parent/guardian to comply with the requirements of the protocol;
- Currently receiving chemotherapy and/or radiation therapy for the treatment of cancer or have received chemotherapy in the past 12 weeks;
- If the subject's underlying cancer is a solid tumor, current status must be stable disease, partial response, or complete response to therapy; if the subject's underlying disease is a hematologic malignancy, current status must be in remission;
- Estimated life expectancy of >1 year; and
- Currently has no worse than mild to moderate immunosuppression (meets none of the exclusion criteria).
Exclusion Criteria:
- History of hypersensitivity to any component of FluMist, including egg or egg products, or monosodium glutamate;
- History of hypersensitivity to gentamicin;
- Close contact with a severely immunocompromised patient (e.g., a hematopoietic stem cell transplant patient, during those periods in which the immunocompromised patient requires care in a protective environment);
- History of Guillain-Barré syndrome;
- History of asthma;
- Use of aspirin or salicylate-containing products in the 30 days prior to study vaccination or expected receipt within the study duration;
- Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and zanamivir) within 14 days prior to enrollment or expected receipt (unless medically indicated) during this study;
- Currently receiving inhaled steroid therapy;
- Receipt of immunoglobulin within the past 90 days;
- Receipt of stem cell transplant;
- Acute febrile [>100.0°F (37.8°C) oral] illness or acute respiratory illness, e.g., cough or sore throat, within three days prior to enrollment;
- Administration of any live vaccine within 30 days prior to enrollment or if receipt of another live vaccine is expected within 30 days after the vaccination in this study;
- Administration of any inactivated vaccine within two weeks prior to enrollment or if receipt of another inactivated vaccine is expected within two weeks after the vaccination in this study;
- Receipt of an investigational product studied under an investigational new drug (IND) within 10 days prior to study entry or expected receipt of such an investigational product within 10 days after study vaccination (Note: an investigational product not studied under an IND is allowed at the investigator's discretion);
- Pregnancy or, in biologically capable females (e.g., menses within the last year), not willing to agree to acceptable birth control for three months after study vaccination (for those biologically capable, a urine pregnancy test must be performed on the day of vaccination with a negative result);
- Female who is breastfeeding or lactating;
- Any condition or receipt of other medication that, in the opinion of the investigator, might interfere with the evaluation of the vaccine or interpretation of study results;
- At the study screening visit (within 16 days before study vaccination) a CD4+ T cell percentage of <15%;
- At study entry, an absolute neutrophil count less than or equal to 500 cells/mm3;
- Receipt of high-dose systemic corticosteroids (≥ 2 mg/kg total of prednisone or equivalent given daily or on alternating days) for ≥ 14 consecutive days within 30 days prior to or following study vaccination
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: FluMist
The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains.
During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003).
During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.
|
The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like. brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm. |
PLACEBO_COMPARATOR: Placebo
Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate.
The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
|
Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate.
The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Had Reactogenicity Events (REs)
Time Frame: 0-42 days after study vaccination
|
Reactogenicity events (REs) are predefined solicited adverse events (AEs) that can potentially occur after vaccine administration.
The REs for this study included fever, runny nose/nasal congestion, sore throat, cough, vomiting, headache, muscle aches, chills, tiredness, and irritability.
|
0-42 days after study vaccination
|
Number of Participants Who Had Serious Adverse Events (SAEs)
Time Frame: 0-180 days after study vaccination
|
An SAE is any AE that results in any of the following outcomes: •Death • Life-threatening • Inpatient hospitalization or prolongation of existing hospitalization • Persistent or significant disability or incapacity • Congenital anomaly/birth defect (in the offspring of a study participant) • An important medical event that may may jeopardize the study participant and may require medical or surgical intervention to prevent one of the outcomes listed above.
|
0-180 days after study vaccination
|
Number of Participants Who Had Adverse Events (AEs)
Time Frame: 0-42 days after study vaccination
|
An AE is any untoward medical occurrence in a patient or clinical investigations study participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
|
0-42 days after study vaccination
|
Number of Significant New Medical Conditions (SNMCs)
Time Frame: 43-180 days after study vaccination
|
A significant new medical condition is defined as a new diagnosis of a chronic medical condition that does not meet the criteria of a SAE.
|
43-180 days after study vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Shedding Vaccine-like Virus
Time Frame: 3-5 days after study vaccination
|
Number of participants with nasal swab samples that contained vaccine-like virus are reported.
|
3-5 days after study vaccination
|
Number of Participants Shedding Vaccine-like Virus
Time Frame: 7-10 days after study vaccination
|
Number of participants with nasal swab samples that contained vaccine-like virus are reported.
|
7-10 days after study vaccination
|
Number of Participants Shedding Vaccine-like Virus
Time Frame: 14-28 days after study vaccination
|
Number of participants with nasal swab samples that contained vaccine-like virus are reported.
|
14-28 days after study vaccination
|
Number of Participants Shedding Vaccine-like Virus
Time Frame: 35-42 days after study vaccination
|
Number of participants with nasal swab samples that contained vaccine-like virus are reported.
Sample was collected at this time point only if health assessment indicated presence of a respiratory illness, including otitis media.
|
35-42 days after study vaccination
|
Number of Participants Shedding Vaccine-like Virus
Time Frame: Unscheduled visits occurring during 0-42 days after study vaccination
|
Number of participants with nasal swab samples that contained vaccine-like virus are reported.
|
Unscheduled visits occurring during 0-42 days after study vaccination
|
T- and B-lymphocyte Subsets by Flow Cytometry - Cluster of Differentiation (CD) 19
Time Frame: pre-dosing (Day 0)
|
Mean and standard deviation results of CD19 lymphocyte subsets as a percentage of total lymphocytes.
|
pre-dosing (Day 0)
|
T- and B-lymphocyte Subsets by Flow Cytometry - CD3
Time Frame: pre-dosing (Day 0)
|
Mean and standard deviation results of CD3 lymphocyte subsets as a percentage of total lymphocytes.
|
pre-dosing (Day 0)
|
T- and B-lymphocyte Subsets by Flow Cytometry - CD4
Time Frame: pre-dosing (Day 0)
|
Mean and standard deviation results of CD4 lymphocyte subsets as a percentage of total lymphocytes.
|
pre-dosing (Day 0)
|
T- and B-lymphocyte Subsets by Flow Cytometry - CD8
Time Frame: pre-dosing (Day 0)
|
Mean and standard deviation results of CD8 lymphocyte subsets as a percentage of total lymphocytes.
|
pre-dosing (Day 0)
|
T- and B-lymphocyte Subsets by Flow Cytometry - CD19
Time Frame: 7-10 days after study vaccination
|
Mean and standard deviation results of CD19 lymphocyte subsets as a percentage of total lymphocytes.
|
7-10 days after study vaccination
|
T- and B-lymphocyte Subsets by Flow Cytometry - CD3
Time Frame: 7-10 days after study vaccination
|
Mean and standard deviation results of CD3 lymphocyte subsets as a percentage of total lymphocytes.
|
7-10 days after study vaccination
|
T- and B-lymphocyte Subsets by Flow Cytometry - CD4
Time Frame: 7-10 days after study vaccination
|
Mean and standard deviation results of CD4 lymphocyte subsets as a percentage of total lymphocytes.
|
7-10 days after study vaccination
|
T- and B-lymphocyte Subsets by Flow Cytometry - CD8
Time Frame: 7-10 days after study vaccination
|
Mean and standard deviation results of CD8 lymphocyte subsets as a percentage of total lymphocytes.
|
7-10 days after study vaccination
|
Interferon (INF)-Gamma
Time Frame: pre-dosing (Day 0)
|
Mean and standard deviation spots-forming cells per 10^5 T cells is reported.
|
pre-dosing (Day 0)
|
INF-Gamma
Time Frame: 7-10 days after study vaccination
|
Mean and standard deviation spots-forming cells per 10^5 T cells is reported.
|
7-10 days after study vaccination
|
INF-Gamma
Time Frame: 35-42 days after study vaccination
|
Mean and standard deviation spots-forming cells per 10^5 T cells is reported.
|
35-42 days after study vaccination
|
Interleukin (IL)-4
Time Frame: pre-dosing (Day 0)
|
Mean and standard deviation spots-forming cells per 10^5 T cells is reported.
|
pre-dosing (Day 0)
|
IL-4
Time Frame: 7-10 days after study vaccination
|
Mean and standard deviation spots-forming cells per 10^5 T cells is reported.
|
7-10 days after study vaccination
|
IL-4
Time Frame: 35-42 days after study vaccination
|
Mean and standard deviation spots-forming cells per 10^5 T cells is reported.
|
35-42 days after study vaccination
|
Human Leukocyte Antigen (HLA) Matched Tetramers CD8+
Time Frame: pre-dosing (Day 0)
|
The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.
|
pre-dosing (Day 0)
|
HLA Matched Tetramers CD8+
Time Frame: 7-10 days after study vaccination
|
The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.
|
7-10 days after study vaccination
|
HLA Matched Tetramers CD8+
Time Frame: 35-42 days after study vaccination
|
The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.
|
35-42 days after study vaccination
|
Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H1N1 Hemagglutination Inhibition (HAI) Titers From Baseline to Day 35-42
Time Frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
|
Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers >= 4 from baseline are reported.
|
Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
|
Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H3N2 HAI Titers From Baseline to Day 35-42
Time Frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
|
Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers >= 4 from baseline are reported.
|
Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
|
Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza B HAI Titers From Baseline to Day 35-42
Time Frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
|
Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers >= 4 from baseline are reported.
|
Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
|
Number of Participants Who Experienced a >= 4-fold Rise in Influenza A/H1N1 Microneutralization Titers From Baseline to Day 35-42
Time Frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
|
Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers >= 4 from baseline are reported.
|
Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
|
Number of Participants Who Experienced a >= 4-fold Rise in Influenza A/H3N2 Microneutralization Titers From Baseline to Day 35-42
Time Frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
|
Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers >= 4 from baseline are reported.
|
Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
|
Number of Participants Who Experienced a >= 4-fold Rise in Influenza B Microneutralization Titers From Baseline to Day 35-42
Time Frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
|
Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers >= 4 from baseline are reported.
|
Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
|
Influenza A/H1N1 Immunoglobulin A (IgA)
Time Frame: pre-dosing (Day 0)
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
pre-dosing (Day 0)
|
Influenza A/H1N1 IgA
Time Frame: 3-5 days after study vaccination
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
3-5 days after study vaccination
|
Influenza A/H1N1 IgA
Time Frame: 7-10 days after study vaccination
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
7-10 days after study vaccination
|
Influenza A/H1N1 IgA
Time Frame: 14-28 days after study vaccination
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
14-28 days after study vaccination
|
Influenza A/H1N1 IgA
Time Frame: 35-42 days after study vaccination
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
35-42 days after study vaccination
|
Influenza A/H3N2 IgA
Time Frame: pre-dosing (Day 0)
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
pre-dosing (Day 0)
|
Influenza A/H3N2 IgA
Time Frame: 3-5 days after study vaccination
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
3-5 days after study vaccination
|
Influenza A/H3N2 IgA
Time Frame: 7-10 days after study vaccination
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
7-10 days after study vaccination
|
Influenza A/H3N2 IgA
Time Frame: 14-28 days after study vaccination
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
14-28 days after study vaccination
|
Influenza A/H3N2 IgA
Time Frame: 35-42 days after study vaccination
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
35-42 days after study vaccination
|
Influenza B IgA
Time Frame: pre-dosing (Day 0)
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
pre-dosing (Day 0)
|
Influenza B IgA
Time Frame: 3-5 days after study vaccination
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
3-5 days after study vaccination
|
Influenza B IgA
Time Frame: 7-10 days after study vaccination
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
7-10 days after study vaccination
|
Influenza B IgA
Time Frame: 14-28 days after study vaccination
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
14-28 days after study vaccination
|
Influenza B IgA
Time Frame: 35-42 days after study vaccination
|
Mean of influenza-specific IgA from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
35-42 days after study vaccination
|
T- and B-lymphocyte Subsets by Flow Cytometry - CD56
Time Frame: pre-dosing (Day 0)
|
Mean and standard deviation results of CD56 lymphocyte subsets is reported.
|
pre-dosing (Day 0)
|
T- and B-lymphocyte Subsets by Flow Cytometry - CD56
Time Frame: 7-10 days after study vaccination
|
Mean and standard deviation results of CD56 lymphocyte subsets is reported.
|
7-10 days after study vaccination
|
T- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells
Time Frame: pre-dosing (Day 0)
|
Mean and standard deviation results of white blood cells subsets is reported.
|
pre-dosing (Day 0)
|
T- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells
Time Frame: 7-10 days after study vaccination
|
Mean and standard deviation results of white blood cells subsets is reported.
|
7-10 days after study vaccination
|
T- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes
Time Frame: pre-dosing (Day 0)
|
Mean and standard deviation results of lymphocytes subsets is reported.
|
pre-dosing (Day 0)
|
T- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes
Time Frame: 7-10 days after study vaccination
|
Mean and standard deviation results of lymphocytes subsets is reported.
|
7-10 days after study vaccination
|
T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes
Time Frame: pre-dosing (Day 0)
|
Mean and standard deviation results of absolute lymphocytes subsets is reported.
|
pre-dosing (Day 0)
|
T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes
Time Frame: 7-10 days after study vaccination
|
Mean and standard deviation results of absolute lymphocytes subsets is reported.
|
7-10 days after study vaccination
|
T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Neutrophils
Time Frame: pre-dosing (Day 0)
|
Mean and standard deviation results of absolute neutrophils subsets is reported.
|
pre-dosing (Day 0)
|
Influenza A/H1N1 Immunoglobulin G (IgG)
Time Frame: pre-dosing (Day 0)
|
Mean of influenza-specific IgG from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
pre-dosing (Day 0)
|
Influenza A/H1N1 IgG
Time Frame: 35-42 days after study vaccination
|
Mean of influenza-specific IgG from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
35-42 days after study vaccination
|
Influenza A/H3N2 IgG
Time Frame: pre-dosing (Day 0)
|
Mean of influenza-specific IgG from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
pre-dosing (Day 0)
|
Influenza A/H3N2 IgG
Time Frame: 35-42 days after study vaccination
|
Mean of influenza-specific IgG from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
35-42 days after study vaccination
|
Influenza B IgG
Time Frame: pre-dosing (Day 0)
|
Mean of influenza-specific IgG from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
pre-dosing (Day 0)
|
Influenza B IgG
Time Frame: 35-42 days after study vaccination
|
Mean of influenza-specific IgG from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
35-42 days after study vaccination
|
Influenza A/H1N1 Immunoglobulin M (IgM)
Time Frame: pre-dosing (Day 0)
|
Mean of influenza-specific IgM from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
pre-dosing (Day 0)
|
Influenza A/H1N1 IgM
Time Frame: 35-42 days after study vaccination
|
Mean of influenza-specific IgM from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
35-42 days after study vaccination
|
Influenza A/H3N2 IgM
Time Frame: pre-dosing (Day 0)
|
Mean of influenza-specific IgM from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
pre-dosing (Day 0)
|
Influenza A/H3N2 IgM
Time Frame: 35-42 days after study vaccination
|
Mean of influenza-specific IgM from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
35-42 days after study vaccination
|
Influenza B IgM
Time Frame: pre-dosing (Day 0)
|
Mean of influenza-specific IgM from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
pre-dosing (Day 0)
|
Influenza B IgM
Time Frame: 35-42 days after study vaccination
|
Mean of influenza-specific IgM from nasal swab is reported.
Titers of < 1 were assigned the value of 0.5.
|
35-42 days after study vaccination
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- MI-CP114
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on FluMist
-
MedImmune LLCAstraZenecaCompletedHealthy | InfluenzaUnited States
-
MedImmune LLCCompletedHealthy or Stable Underlying Chronic Medical ConditionUnited States
-
MedImmune LLCCompleted
-
MedImmune LLCCompletedHealthy or Stable Chronic IllnessUnited States
-
MedImmune LLCCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes...WithdrawnInfluenzaUnited States
-
University of North Carolina, Chapel HillMedImmune LLC; University of North CarolinaCompleted
-
MedImmune LLCCompletedHealthyUnited States
-
MedImmune LLCCompleted